EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Design and In Vitro Evaluation of a Novel Antisense Oligonucleotide for Treatment of BK Virus Infection

Jurriën Prins iD, Janneke Kouwenberg, Anouk Spruit, Lizanne Daleman, Iris van Wissen, Bianca Matthee, Angela Koudijs, Caroline de Brouwer, Ellen Lievers, Franca Witjas, Vita Dauksaite, Carla van Alem und 10 weitere

Nucleic Acid Therapeutics · 01.08.2025 · 35 (4) · 182-197

DOI: 10.1089/nat.2025.0010 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nucleic Acid Therapeutics, online erschienen am 04.06.2025. Verfasst von Jurriën Prins und 21 weiteren Autor:innen. Beteiligte Einrichtung: Hybridize Therapeutics, The Hague, The Netherlands. Hauptthemen laut MEDLINE: BK Virus, Oligonucleotides, Antisense, Polyomavirus Infections, Antiviral Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BK polyomavirus, a virus that latently resides in tubular epithelial cells of human kidneys, represents a major clinical problem for immunocompromised patients undergoing kidney transplantation. No proven effective specific antiviral therapies other than reduction of immunosuppressants exist. We exploited splice-modulating antisense oligonucleotides (ASOs) to block expression of the viral “gatekeeper protein” T antigen to specifically inhibit viral replication. Candidate oligonucleotides were screened for inhibitory activity in BK virus-infected cells, resulting in up to 97% reduction of viral T antigen mRNA and virus-encapsulating protein. The most promising ASO candidates were validated in BK virus-infected human kidney epithelial cells, showing sequence-specific activity that was exacerbated by chemical modifications. Administration of the candidate oligonucleotide in mice revealed long-lasting uptake in proximal tubules of the kidney, where BK virus resides. A final optimization round yielded an oligonucleotide displaying superior activity. Studies in transformed cells revealed a discernible shift in T antigen splicing not observed with a scrambled control, indicating that targeting of the donor splice site was responsible for the observed effects. Here, we demonstrate proof-of-principle for a direct-acting, splice-modulating, universal ASO that distributes to sites where BK viral replication occurs, warranting further development of this novel therapeutic to combat BK virus replication in kidney transplant patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BK VirusOligonucleotides, AntisensePolyomavirus InfectionsAntiviral AgentsHumansAnimalsMiceVirus ReplicationAntigens, Viral, TumorEpithelial CellsRNA SplicingCell Line

Stichwörter der Autor:innen

BK virusRNA-based drugsantisense oligonucleotidesantiviral therapykidney transplantationlarge T antigensplicing interference

Substanzen

Oligonucleotides, AntisenseAntigens, Viral, TumorAntiviral Agents

Autor:innen und Institutionen

  • Hybridize Therapeutics, The Hague, The Netherlands.
  • Department of Internal Medicine (Nephrology), Leiden University Medical Center, Leiden, The Netherlands.
  • Einthoven Laboratory for Vascular and Regenerative Medicine, Leiden University Medical Center, Leiden, The Netherlands.
  • Department of Medical Microbiology & Infection Control, Leiden University Center of Infectious Diseases, Leiden University Medical Center, Leiden, The Netherlands.
  • Department of Human Genetics, Leiden University Medical Center, Leiden, The Netherlands.
  • AiCuris Anti-infective Cures AG, Wuppertal, Germany.

ORCID-Profile: Jurriën Prins, Annemieke Aartsma-Rus, Anton Jan van Zonneveld

Zitieren

APA

Prins, J., Kouwenberg, J., Spruit, A., Daleman, L., van Wissen, I., Matthee, B., Koudijs, A., de Brouwer, C., Lievers, E., Witjas, F., Dauksaite, V., van Alem, C., Bijkerk, R., Aartsma-Rus, A., Sipkens, J., Rabelink, T., Feltkamp, M., Pfaff, T., Zimmermann, H., …, & van der Veer, E. (2025). Design and In Vitro Evaluation of a Novel Antisense Oligonucleotide for Treatment of BK Virus Infection. Nucleic Acid Therapeutics, 35(4), 182-197. https://doi.org/10.1089/nat.2025.0010

Vancouver

Prins J, Kouwenberg J, Spruit A, Daleman L, van Wissen I, Matthee B, et al. Design and In Vitro Evaluation of a Novel Antisense Oligonucleotide for Treatment of BK Virus Infection. Nucleic Acid Therapeutics. 2025;35(4):182-197. doi:10.1089/nat.2025.0010

BibTeX
@article{Prins2025,
  author = {Prins, Jurriën and Kouwenberg, Janneke and Spruit, Anouk and Daleman, Lizanne and van Wissen, Iris and Matthee, Bianca and Koudijs, Angela and de Brouwer, Caroline and Lievers, Ellen and Witjas, Franca and Dauksaite, Vita and van Alem, Carla and Bijkerk, Roel and Aartsma-Rus, Annemieke and Sipkens, Jessica and Rabelink, Ton and Feltkamp, Mariet and Pfaff, Tamara and Zimmermann, Holger and van Zonneveld, Anton Jan and Lischka, Peter and van der Veer, Eric},
  title = {Design and In Vitro Evaluation of a Novel Antisense Oligonucleotide for Treatment of BK Virus Infection},
  journal = {Nucleic Acid Therapeutics},
  year = {2025},
  volume = {35},
  number = {4},
  pages = {182--197},
  doi = {10.1089/nat.2025.0010}
}
Kostenlos starten →